Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Resmed (0KW4) Share Price & Analysis

0 Followers

0KW4 Stock Chart & Stats

$233.56-$2.60(-0.14%)
At close: 4:30 PM GMT
$220$230$240$250Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$231.27 - $239.28
52-Week Range
$180.60 - $277.17
Previous Close
$233.89
Volume
N/A
Average Volume (3M)
461
Market Cap
$32.93B
Enterprise Value
$31.29B
Total Cash (Recent Filing)
$1.01B
Total Debt (Recent Filing)
$610.58M
Price to Earnings (P/E)
21.3
Beta
0.65
Next Earnings
Jan 28, 2027 (Est.)
EPS Estimate
2.99
Last Dividend Ex-Date
Nov 11, 2026
Dividend Yield
1.08%

Bulls Say, Bears Say

Bulls Say

Strong Profitability And Cash Generation

High margins and strong conversion of earnings into operating and free cash flow give ResMed financial flexibility to fund innovation, absorb business changes, and return capital. This durable cash engine supports resilience and reinforces the company’s ability to invest across its sleep and respiratory platforms.

Connected Ecosystem Improves Adherence

A large connected-user base and measurable adherence gains deepen ResMed’s relationship with patients and providers beyond the initial device sale. The ecosystem can support recurring resupply, strengthen customer retention, and create durable data advantages across connected care workflows.

Product Breadth And Growth Outlook

Reiterated growth and margin guidance indicates management expects the core portfolio to expand while becoming more profitable. New mask, bilevel, digital-health, and residential-care offerings broaden the addressable market and provide multiple avenues for sustained earnings growth.

Bears Say

Astral Discontinuation Reduces Growth

The Astral decision removes an established revenue stream and creates a meaningful near-term drag on reported growth. Although the action addresses a field safety issue, replacing that contribution will require strength elsewhere in the portfolio and may weigh on respiratory-care scale over coming quarters.

Inflation And Expansion Costs Pressure Margins

Rising component costs and facility start-up expenses can temporarily dilute operating leverage even as productivity programs support longer-term improvement. These pressures may constrain margin progression and require continued execution on procurement, manufacturing efficiency, and capacity utilization.

Free Cash Flow Has Weakened Year Over Year

Lower free cash flow reduces the near-term cash available for reinvestment, acquisitions, and shareholder returns, even though overall cash generation remains strong. Inventory investment and tax prepayments may normalize, but the decline signals less predictable cash conversion during the current transition.

Resmed News

0KW4 FAQ

What was Resmed’s price range in the past 12 months?
Resmed lowest share price was $180.60 and its highest was $277.17 in the past 12 months.
What is Resmed’s market cap?
Resmed’s market cap is $32.93B.
When is Resmed’s upcoming earnings report date?
Resmed’s next earnings report is estimated for Jan 28, 2027 (not yet confirmed), which is in 77 days.
How were Resmed’s earnings last quarter?
Resmed released its earnings results on Oct 29, 2026. The company reported $2.91 earnings per share for the quarter, beating the consensus estimate of $2.686 by $0.224.
Is Resmed overvalued?
According to Wall Street analysts Resmed’s price is currently Undervalued.
Does Resmed pay dividends?
Resmed pays a quarterly dividend of $0.66 which represents an annual dividend yield of 1.08%. See more information on Resmed dividends here
What is Resmed’s EPS estimate?
Resmed’s EPS estimate is 2.99.
How many shares outstanding does Resmed have?
Resmed has 140,657,070 shares outstanding.
What happened to Resmed’s price movement after its last earnings report?
Resmed reported an EPS of $2.91 in its last earnings report, beating expectations of $2.686. Following the earnings report the stock price went down -7.288%.
Which hedge fund is a major shareholder of Resmed?
Hedge funds hold Resmed shares: the largest hedge-fund position in Resmed is 1,693,722,409 shares, and hedge funds increased their holdings by 29.4K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology